July 26, 2019 — Oncology company Progenics Pharmaceuticals Inc. announced their collaboration with the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS) on Progenics’ artificial intelligence (AI) research program. The collaborative AI research program aims to apply machine learning to medical imaging modalities, enabling standardized, information-driven healthcare practices in prostate cancer. The project is the nation’s first collaborative effort to validate cutting-edge machine learning tools for improving treatment management of veterans with prostate cancer.
Progenics CEO Mark Baker said the company believes that AI can be applied successfully to automate the segmentation, classification and quantification of tumors. Matthew Rettig, M.D., chief of hematology-oncology at VAGLAHS, will be one of the leads on the project.
In the project, the VAGLAHS network will gain access to Progenics’ machine learning platforms, which includes the automated Bone Scan Index (aBSI) and the PSMA-AI platforms. The collaboration would explore novel predictive machine learning algorithms from the digital medical images and its associated clinical outcomes. These novel algorithms would be prospectively validated at VAGLAHS for effective healthcare management of veterans with prostate cancer.
The research collaboration will take every step necessary to protect the veterans’ data. All image and associated clinical data would be anonymized before being processed by the Progenics’ AI platform. Progenics’ AI platform is designed, developed, deployed and maintained according to cybersecurity guidance; NIST cybersecurity framework, the Open Web Application Security Project (OWASP). All data handled by the platform is encrypted in transit and at rest.
For more information: www.progenics.com
March 11, 2026 
